Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

222.15
+4.772.19%
Post-market: 222.150.00000.00%19:11 EST
Volume:805.54K
Turnover:176.46M
Market Cap:13.71B
PE:-48.95
High:223.24
Open:217.73
Low:212.70
Close:217.38
52wk High:242.00
52wk Low:118.03
Shares:61.70M
Float Shares:60.08M
Volume Ratio:1.30
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5384
EPS(LYR):-6.7615
ROE:-818.43%
ROA:-7.69%
PB:-66.62
PE(LYR):-32.86

Loading ...

Health Canada genehmigt Yorvipath von Ascendis Pharma für die Behandlung von chronischem Hypoparathyreoidismus

Reuters
·
7 hours ago

Ascendis Pharma A/S to Announce Full Year 2025 Financial Results and Business Update

Reuters
·
Feb 05

Ascendis Pharma price target raised to $260 from $246 at BofA

TIPRANKS
·
Jan 30

Ascendis Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Jan 30

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading

MT Newswires Live
·
Jan 29

Ascendis Pharma Initiated at Overweight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on Ascendis Pharma With Overweight Rating, $342 Price Target

MT Newswires Live
·
Jan 28

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
Jan 27

Ascendis Pharma rumor highlighted in Betaville blog

TIPRANKS
·
Jan 23

Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Ascendis Pharma (ASND)

TIPRANKS
·
Jan 21

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

MT Newswires Live
·
Jan 21

RBC Raises Price Target on Ascendis Pharma to $250 From $245, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 20

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Ascendis Pharma (ASND)

TIPRANKS
·
Jan 20

Ascendis Pharma a/S : Leerink Partners Raises Target Price to $290 From $225

THOMSON REUTERS
·
Jan 20

Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results

Simply Wall St.
·
Jan 17

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Rise 2% for Week

MT Newswires Live
·
Jan 17

Ascendis Pharma price target raised to $246 from $242 at BofA

TIPRANKS
·
Jan 12

Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026

Reuters
·
Jan 10

Ascendis Pharma A/S outlines strategy to expand rare disease portfolio and target blockbuster revenues

Reuters
·
Jan 10

Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program

Reuters
·
Jan 10